Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruiting
NCT07205822Phase 3Updated Jul 27, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, China, France, Italy, South Korea +1 more
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusActive Not Recruiting
NCT04877691Phase 3Updated Jul 27, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Argentina, Bulgaria, Chile, Colombia +10 more
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive Not Recruiting
NCT03298451Phase 3Updated Jul 27, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Brazil, Canada, China, France +12 more
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.Active Not Recruiting
NCT06992609Phase 3Updated Jul 27, 2026
Sponsor: AstraZeneca
Small Cell Lung Carcinoma
Spain
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in BrazilRecruiting
NCT07370194N/AUpdated Jul 24, 2026
Sponsor: AstraZeneca
Hyperkalemia
Brazil
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompleted
NCT06040086Phase 3Updated Jul 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Belgium, Brazil, Bulgaria +24 more
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsActive Not Recruiting
NCT02264678Phase 1Updated Jul 24, 2026
Sponsor: AstraZeneca
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
United States, France, South Korea, United Kingdom
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug ZTerminated
NCT06929260Phase 1Updated Jul 24, 2026
Sponsor: AstraZeneca
Advanced Solid Tumours
United Kingdom
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemRecruiting
NCT07361276N/AUpdated Jul 24, 2026
Sponsor: AstraZeneca
Hypertension
Brazil
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and HyperinflationRecruiting
NCT07073950Phase 4Updated Jul 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease · Hyperinflation
Germany, United Kingdom
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)Completed
NCT04553926N/AUpdated Jul 23, 2026
Sponsor: AstraZeneca
Ovarian Cancer · Breast Cancer · Prostate Cancer · Pancreatic Cancer
South Korea
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active Not Recruiting
NCT05925803Phase 3Updated Jul 23, 2026
Sponsor: AstraZeneca
Systemic Sclerosis · Scleroderma
United States, Austria, Belgium, Canada, China +18 more
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNot Yet Recruiting
NCT07683754Phase 3Updated Jul 23, 2026
Sponsor: Daiichi Sankyo
Advanced Breast Cancer · Metastatic Breast Cancer · HER2 Positive · HR Positive
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and DurvalumabRecruiting
NCT06796114NAUpdated Jul 23, 2026
Sponsor: Centre Hospitalier Universitaire de Besancon
Hepatocellular Carcinoma
France
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.Recruiting
NCT06916806Phase 1Updated Jul 23, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus · Idiopathic Inflammatory Myopathies · Rheumatoid Arthritis
United States, Canada, China, France, Germany +5 more
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruiting
NCT07720284Phase 3Updated Jul 22, 2026
Sponsor: AstraZeneca
High-risk Muscle Invasive Urothelial Carcinoma
United States, Australia, Brazil, Canada, China +11 more
DESTINY-PANTUMOUR04Recruiting
NCT07124000N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Adenocarcinoma (NOS) · Anal Cancer · Bladder Cancer · Cervical Cancer
United States
The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP"Recruiting
NCT07663409N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
CRSwNP or CRSsNP Patients
Greece
Increasing Adherence to Lung Cancer ScreeningCompleted
NCT05832008NAUpdated Jul 22, 2026
Sponsor: Abramson Cancer Center at Penn Medicine
Lung Cancer · Adherence, Patient
United States
Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 AgonistNot Yet Recruiting
NCT07718724NAUpdated Jul 22, 2026
Sponsor: AstraZeneca
Uncontrolled Asthma
China
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in BrazilRecruiting
NCT06491862N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Non-squamous Non-Small Cell Lung Cancer
Brazil
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.Recruiting
NCT06417801N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Metastatic Breast Cancer
Brazil
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian CohortRecruiting
NCT07101081N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Gynaecological Cancers
Brazil
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCTerminated
NCT04163432Phase 2Updated Jul 22, 2026
Sponsor: University of Utah
Non-Small Cell Lung Cancer Metastatic
United States
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome PatientsActive Not Recruiting
NCT06099236N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Atypical Hemolytic Uremic Syndrome(aHUS)
China

Previous page Next page